MEDIA/INVESTORS CONTACT:
Jonathan Fassberg
The Trout Group
(212) 477-9077 x16
CYTOGEN ANNOUNCES RETIREMENT OF THOMAS LYTLE AS SENIOR VICE PRESIDENT OF SALES
AND MARKETING
PRINCETON, N.J., (September 26, 2005) -- Cytogen Corporation (Nasdaq: CYTO)
today announced that Thomas S. Lytle, 59, has decided to retire from his
position as senior vice president of sales and marketing effective October 31,
2005.
Mr. Lytle will become a consultant to the company, focusing on expanding its
relationships with key physicians and customers and developing new models to
improve patient access to Cytogen's oncology products. In this capacity, he will
continue to work with key customers and accounts in developing and implementing
these concepts.
Michael D. Becker, Cytogen's president and chief executive officer, stated: "Tom
Lytle has played an important role in expanding our sales force and marketing
programs during the past year. We have benefited from the knowledge and
experience he gained through 35 years in the pharmaceutical industry and wish
him all the best during this next chapter of his life."
The company has no current plans to fill Mr. Lytle's position. Effective
immediately, Mr. Becker will assume a broader role in leading the sales and
marketing team at Cytogen.
ABOUT CYTOGEN CORPORATION
- -------------------------
Founded in 1980, Cytogen Corporation of Princeton, NJ is a product-driven
biopharmaceutical company that develops and commercializes innovative molecules
that can be used to build leading franchises. Cytogen's marketed products
include QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R)
(capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide
in the United States. Cytogen also has exclusive United States marketing rights
to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to
market and sell ferumoxytol (previously Code 7228) for oncology applications in
the United States. Cytogen's development pipeline consists of therapeutics
targeting prostate-specific membrane antigen (PSMA), a protein highly expressed
on the surface of prostate cancer cells and the neovasculature of solid tumors.
Full prescribing information for the Company's products is available at
www.cytogen.com or by calling 1-800-833-3533. For more information, please visit
the Company's website at www.cytogen.com, which is not part of this press
release.
This press release contains certain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended. All statements, other than
statements of historical facts, included in this press release regarding our
strategy, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and investors are cautioned not to put any undue reliance on any
forward-looking statement. There are a number of important factors that could
cause Cytogen's results to differ materially from those indicated by such
forward-looking statements. In particular, Cytogen's business is subject to a
number of significant risks, which include, but are not limited to: the risk of
obtaining the necessary regulatory approvals; the risk of whether products
result from development activities; the risk of shifts in the regulatory
environment affecting sales of
Cytogen's products such as third-party payor reimbursement issues; the risk
associated with Cytogen's dependence on its partners for development of certain
projects, as well as other factors expressed from time to time in Cytogen's
periodic filings with the Securities and Exchange Commission (the "SEC"). As a
result, this press release should be read in conjunction with Cytogen's periodic
filings with the SEC. The forward-looking statements contained herein are made
only as of the date of this press release, and Cytogen undertakes no obligation
to publicly update such forward-looking statements to reflect subsequent events
or circumstances.
###